Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Wages, Salaries and Other

Ratios

Corvus Pharmaceuticals (CRVS) Shares Repurchased (2016)

Corvus Pharmaceuticals' Shares Repurchased history spans 1 years, with the latest figure at -$1000.0 for Q4 2016.

Quarterly Shares Repurchased changed N/A to -$1000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $71.4 million through Dec 2016, changed N/A year-over-year, with the annual reading at $71.4 million for FY2016, N/A changed from the prior year.
Shares Repurchased came in at -$1000.0 for Q4 2016, down from $7.0 million in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $64.3 million in Q1 2016 to a low of -$1000.0 in Q4 2016.